Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions

Lovecek M., Dirimtekin E., Garajová I., Gasparini G., Crippa S., Giovannetti E.

Narrative Review on Systemic / IV, published in United European Gastroenterol J (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
United European Gastroenterol J (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40981722
PMCID
PMC12606004
DOI
10.1002/ueg2.70118
Citations
3

Abstract (original English)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, mainly due to its aggressive nature, early metastasis, diagnosis at late stages, and limited response to systemic anticancer therapy. Perineural invasion (PNI), defined as the infiltration of neoplastic cells along nerve fibers and within nerve sheaths, is emerging as a critical determinant of PDAC aggressiveness. This position paper by the TRANSPAN PNI Group on Perineural Invasion synthesizes current evidence on the molecular features and clinical implications of PNI in PDAC, compares its prognostic significance in other malignancies, and describes novel biomarker strategies including potential therapeutic interventions.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Nerve FibersPeripheral NervesHumansCarcinoma, Pancreatic DuctalPancreatic NeoplasmsNeoplasm InvasivenessPrognosisBiomarkers, Tumor

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research